TerrAscend Reports First Quarter 2026 Financial Results

• TerrAscend Corp. reported Q1 2026 financial results on May 7, 2026, confirming preliminary figures released April 27, 2026.
• Net revenue reached $65.5 million, representing a modest year-over-year increase of approximately 1.9% compared to $64.3 million in Q1 2025.
• Gross profit margin decreased slightly to 52.8% from 53.9% in the prior year period but remained stable quarter-over-quarter against Q4 2025 (52.1%).
• GAAP net loss from continuing operations narrowed to $6.8 million, down from a $7.7 million loss in Q1 2025.
• Adjusted EBITDA stood at $17.4 million, representing a margin of 26.5% of net revenue.
• The company achieved its 15th consecutive quarter of positive cash flow from continuing operations and 11th consecutive quarter of positive free cash flow ($7.8 million).
• Cash and cash equivalents increased to $39.1 million as of March 31, 2026.
• Regulatory update notes the U.S. Department of Justice reclassification of medical cannabis to Schedule III, which eliminates the Section 280E tax burden.
• Management change: Eric Jackson appointed Chief Financial Officer effective April 2026.
• Share repurchase activity included 115,000 shares at a weighted average price of $0.66 USD during Q1.

• The financial results are in line with the preliminary announcement made on April 27, 2026, indicating no surprise beat or miss that would trigger immediate material re-pricing based solely on earnings numbers.
• Revenue growth is minimal (+1.9% YoY), suggesting operational momentum has plateaued rather than accelerated despite the regulatory tailwinds mentioned.
• The elimination of the Section 280E tax burden due to Schedule III reclassification is a significant long-term fundamental improvement, but its full impact on net income may not be fully realized in Q1 GAAP results given the continued $6.8 million loss.
• The appointment of Eric Jackson as CFO adds credibility and industry expertise, which could improve investor confidence, though it does not constitute an immediate capital injection or strategic investment by a major shareholder.
• Positive cash flow streak (15 quarters operating, 11 quarters free) validates the company's ability to fund operations without dilution, reducing near-term financing risk.
• Overall impact is positive but incremental; the market likely anticipated these results given the preliminary release and the known regulatory environment changes.

• Company: TerrAscend Corp. is a vertically integrated cannabis operator with a focus on retail dispensaries and cultivation facilities in the United States and Canada.
• Flagship Project: The Apothecarium retail network, which operates high-performing stores across key U.S. markets including New Jersey, Pennsylvania, Maryland, Ohio, and previously Michigan (now discontinued).
• Development Status: Currently expanding production capacity in Pennsylvania with new cultivation rooms completed.
• Operational Scope: Financial results exclude Michigan operations as of Q2 2025, which have been classified as discontinued operations to streamline focus on profitable U.S. markets.